Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes - PubMed (original) (raw)
Clinical Trial
. 2002 Jul;51(7):2074-81.
doi: 10.2337/diabetes.51.7.2074.
Michael F Hirshman, Jonas Nygren, Monika Svanfeldt, Peter Bavenholm, Olav Rooyackers, Gaochao Zhou, Joanne M Williamson, Olle Ljunqvist, Suad Efendic, David E Moller, Anders Thorell, Laurie J Goodyear
Affiliations
- PMID: 12086935
- DOI: 10.2337/diabetes.51.7.2074
Clinical Trial
Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes
Nicolas Musi et al. Diabetes. 2002 Jul.
Abstract
Metformin is an effective hypoglycemic drug that lowers blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in skeletal muscle; however, the molecular site of metformin action is not well understood. AMP-activated protein kinase (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis. We recently reported that AMPK is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production. In the present study, we evaluated whether therapeutic doses of metformin increase AMPK activity in vivo in subjects with type 2 diabetes. Metformin treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity. The increase in AMPK alpha2 activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after metformin treatment. Metformin-induced increases in AMPK activity were associated with higher rates of glucose disposal and muscle glycogen concentrations. These findings suggest that the metabolic effects of metformin in subjects with type 2 diabetes may be mediated by the activation of AMPK alpha2.
Similar articles
- Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects.
Luna V, Casauban L, Sajan MP, Gomez-Daspet J, Powe JL, Miura A, Rivas J, Standaert ML, Farese RV. Luna V, et al. Diabetologia. 2006 Feb;49(2):375-82. doi: 10.1007/s00125-005-0112-4. Epub 2006 Jan 5. Diabetologia. 2006. PMID: 16395615 Clinical Trial. - Role of AMP-activated protein kinase in mechanism of metformin action.
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Zhou G, et al. J Clin Invest. 2001 Oct;108(8):1167-74. doi: 10.1172/JCI13505. J Clin Invest. 2001. PMID: 11602624 Free PMC article. - Isoleucine, a blood glucose-lowering amino acid, increases glucose uptake in rat skeletal muscle in the absence of increases in AMP-activated protein kinase activity.
Doi M, Yamaoka I, Nakayama M, Mochizuki S, Sugahara K, Yoshizawa F. Doi M, et al. J Nutr. 2005 Sep;135(9):2103-8. doi: 10.1093/jn/135.9.2103. J Nutr. 2005. PMID: 16140883 - AMP-activated protein kinase and type 2 diabetes.
Musi N. Musi N. Curr Med Chem. 2006;13(5):583-9. doi: 10.2174/092986706776055724. Curr Med Chem. 2006. PMID: 16515522 Review. - Targeting the AMP-activated protein kinase for the treatment of type 2 diabetes.
Musi N, Goodyear LJ. Musi N, et al. Curr Drug Targets Immune Endocr Metabol Disord. 2002 Jul;2(2):119-27. Curr Drug Targets Immune Endocr Metabol Disord. 2002. PMID: 12476786 Review.
Cited by
- Drug risks associated with sarcopenia: a real-world and GWAS study.
Zhang Z, Yao L. Zhang Z, et al. BMC Pharmacol Toxicol. 2024 Nov 7;25(1):84. doi: 10.1186/s40360-024-00813-y. BMC Pharmacol Toxicol. 2024. PMID: 39511635 Free PMC article. - Metformin: Diverse molecular mechanisms, gastrointestinal effects and overcoming intolerance in type 2 Diabetes Mellitus: A review.
Mohamed S. Mohamed S. Medicine (Baltimore). 2024 Oct 25;103(43):e40221. doi: 10.1097/MD.0000000000040221. Medicine (Baltimore). 2024. PMID: 39470509 Free PMC article. Review. - Antidiabetic and Antihyperlipidemic Activities and Molecular Mechanisms of Phyllanthus emblica L. Extract in Mice on a High-Fat Diet.
Lin HY, Lin CH, Kuo YH, Shih CC. Lin HY, et al. Curr Issues Mol Biol. 2024 Sep 20;46(9):10492-10529. doi: 10.3390/cimb46090623. Curr Issues Mol Biol. 2024. PMID: 39329975 Free PMC article. - An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models.
Toma T, Miyakawa N, Arakaki Y, Watanabe T, Nakahara R, Ali TFS, Biswas T, Todaka M, Kondo T, Fujita M, Otsuka M, Araki E, Tateishi H. Toma T, et al. Diabetologia. 2024 Nov;67(11):2568-2584. doi: 10.1007/s00125-024-06260-y. Epub 2024 Sep 9. Diabetologia. 2024. PMID: 39251430 - Unlocking the Nexus of Sirtuins: A Comprehensive Review of Their Role in Skeletal Muscle Metabolism, Development, and Disorders.
Gibril BAA, Xiong X, Chai X, Xu Q, Gong J, Xu J. Gibril BAA, et al. Int J Biol Sci. 2024 Jun 3;20(8):3219-3235. doi: 10.7150/ijbs.96885. eCollection 2024. Int J Biol Sci. 2024. PMID: 38904020 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases